Drug data last refreshed 2h ago · AI intelligence enriched 1mo ago
VALTREX is an oral antiviral medication approved in 1995 for the treatment of herpesvirus infections. The drug is a small molecule that inhibits viral DNA replication in herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. It represents a foundational therapy in the antiviral treatment landscape.
Product approaching loss of exclusivity with modest Part D spending, indicating a maturing brand with potential team restructuring ahead.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)
Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
Fed Study of Valacyclovir Hydrochloride Tablets 1000 mg and Valtrex® Tablets 1000 mg
Food Study of Valacyclovir Hydrochloride Tablets 1000 mg to Valtrex® Tablets 1000 mg
Worked on VALTREX at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moVALTREX offers limited current hiring momentum (0 linked jobs), reflecting its LOE status and mature market position. Career roles focus on defending market share and managing transition to generic competition rather than growth and launch activities.